Potent immunomodulatory effects of the trifunctional antibody catumaxomab

Diane Goéré, Caroline Flament, Sylvie Rusakiewicz, Vichnou Colame Poirier, Oliver Kepp, Isabelle Martins, Julien Pesquet, Alexander Eggermont, Dominique Elias, Nathalie Chaput, Laurence Zitvogel

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

40 Citaten (Scopus)


Catumaxomab (CatmAb), a trifunctional bispecific antibody directed against the epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3, is approved as intraperitoneal therapy for the treatment of malignant ascites in patients with EpCAM-positive carcinomas. The immunomonitoring results of a phase II/III study using CatmAb revealed a tumoricidal effect associated with reduced VEGF levels, CD69-expressing T cells, and the release of T-helper cell (TH)-1 cytokines. We comprehensively dissected the immunomodulatory effects of the CatmAb on the major subsets of malignant ascites-infiltrating leukocytes and the molecular fingerprint of tumor cell death. Herein we show that in the presence of EpCAM-positive tumor targets, CatmAb markedly enhanced T-cell activation [CD69, CD107A (LAMP1), HLA-DR and PD-1(PDCD1) expression] and stimulated inflammatory CD4+ TH1 and CD8+ TH1 to release IFN-g but failed to trigger TH17 cells. Engagement of CD16-expressing cells caused upregulation of TRAIL (TNFSF10) and costimulatory CD40 and CD80 molecules. CatmAb promoted tumor cell death associated with ATP release and strongly synergized with oxaliplatin for the exposure of the three hallmarks of immunogenic cell death (calreticulin, HMGB1, and ATP). These findings warrant validation as potential biomarkers of efficacy of CatmAb.

Originele taal-2Engels
Pagina's (van-tot)4663-4673
Aantal pagina's11
TijdschriftCancer Research
Nummer van het tijdschrift15
StatusGepubliceerd - 1 aug. 2013
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Potent immunomodulatory effects of the trifunctional antibody catumaxomab'. Samen vormen ze een unieke vingerafdruk.

Citeer dit